Bright Minds Biosciences Files 6-K with Redacted News Release
Ticker: DRUG · Form: 6-K · Filed: Oct 18, 2024 · CIK: 1827401
Sentiment: neutral
Topics: sec-filing, 6-K, news-release
TL;DR
Bright Minds Biosciences filed a 6-K with a news release, but parts are redacted for US distribution.
AI Summary
Bright Minds Biosciences Inc. filed a Form 6-K on October 18, 2024, to submit a news release dated October 18, 2024. The news release was embargoed against distribution to United States newswire services and dissemination in the United States. Portions of the news release have been redacted to comply with U.S. Securities Act rules.
Why It Matters
This filing indicates that Bright Minds Biosciences Inc. is providing updated information to the SEC, but the redactions suggest sensitive or preliminary details are being withheld from immediate public U.S. disclosure.
Risk Assessment
Risk Level: medium — The filing itself is routine, but the embargo and redactions on the news release suggest potential uncertainty or strategic information being managed, which could impact investor perception.
Key Numbers
- 6-K — Form Type (Standard SEC filing for foreign private issuers)
Key Players & Entities
- BRIGHT MINDS BIOSCIENCES INC. (company) — Filer
- October 18, 2024 (date) — Filing and News Release Date
- 19 Vestry Street, New York, NY 10013 (address) — Company Address
- 001-40997 (company_id) — SEC File Number
FAQ
What is the specific reason for the embargo and redactions in the news release?
The filing states the news release was embargoed against distribution to United States newswire services and dissemination in the U.S., and portions were redacted to comply with Rule 135c under the U.S. Securities Act of 1933, but does not specify the exact content redacted.
When was the news release dated and submitted?
The news release is dated October 18, 2024, and the Form 6-K filing was also made on October 18, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 19 Vestry Street, New York, NY 10013.
Does Bright Minds Biosciences file annual reports under Form 20-F or 40-F?
Bright Minds Biosciences Inc. files annual reports under cover of Form 20-F, as indicated by the checkmark next to 'Form 20-F'.
What is the SEC file number for Bright Minds Biosciences Inc.?
The SEC file number for Bright Minds Biosciences Inc. is 001-40997.
Filing Stats: 212 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2024-10-18 16:02:17
Filing Documents
- f6k20241018.htm (6-K) — 5KB
- ex991-20241018.htm (EX-99.1) — 9KB
- ex99120241018_1.jpg (GRAPHIC) — 4KB
- 0001183740-24-000081.txt ( ) — 20KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F [ X ] Form 40-F [ ] SUBMITTED HEREWITH Exhibits 99.1 News Release dated October 1 8 , 2024 * * This news release was embargoed against distribution to United States newswire services, and from dissemination in the United States, pursuant to Rule 135e under the United States Securities Act of 1933, as amended. Certain portions of the news release, as furnished to the SEC hereby, have been redacted to comply with Rule 135c under the U.S. Securities Act. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BRIGHT MINDS BIOSCIENCES INC. /s/ Ryan Cheung __________________________ Ryan Cheung Chief Financial Officer Date: October 18, 2024